The Russian Ministry of Health announced today, Friday, the start of the clinical trials for the Russian “Entromix” anti-tumor vaccine, indicating that the vaccine is currently undergoing the first phase of trials focused on determining the dosage amount and assessing its impact on the patient's body.
The Russian Ministry stated in a press release: “The trials are being conducted at the National Center for Radiation Medical Research affiliated with the Russian Ministry of Health, and include in their first phase the evaluation of safety and appropriate dosages. After completing this phase and approving its results, the research will move to the second and third phases, where the therapeutic efficacy of the vaccine will be evaluated on a broader range of patients.”
